 |
|
Ocular Motility Changes After Subtenon Carboplatin Chemotherapy for Retinoblastoma
Alan Mulvihill, MB, FRCSI;
Andrew Budning, MD, FRCSC;
Venita Jay, MB, BS, FRCPC;
Cynthia Vandenhoven, BA;
Elise Heon, MD, FRCSC;
Brenda L. Gallie, MD, FRCSC;
Helen S. L. Chan, MB, BS, FRCPC
Arch Ophthalmol. 2003;121:1120-1124.
Background Focal subtenon carboplatin injections have recently been used as a presumably toxicity-free adjunct to systemic chemotherapy for intraocular retinoblastoma.
Objective To report our clinical experience with abnormal ocular motility in patients treated with subtenon carboplatin chemotherapy.
Methods We noted abnormal ocular motility in 10 consecutive patients with retinoblastoma who had received subtenon carboplatin. During ocular manipulation under general anesthesia, we assessed their eyes by forced duction testing, comparing ocular motility after tumor control with ocular motility at diagnosis. Eyes subsequently enucleated because of treatment failure (n = 4) were examined histologically.
Results Limitation of ocular motility was detected in all 12 eyes of 10 patients treated for intraocular retinoblastoma with 1 to 6 injections of subtenon carboplatin as part of multimodality therapy. Histopathological examination revealed many lipophages in the periorbital fat surrounding the optic nerve in 1 eye, indicative of phagocytosis of previously existing fat cells and suggesting prior fat necrosis. The enucleations were technically difficult and hazardous for globe rupture because of extensive orbital soft tissue adhesions.
Conclusions Subtenon carboplatin chemotherapy is associated with significant fibrosis of orbital soft tissues, leading to mechanical restriction of eye movements and making subsequent enucleation difficult. Subtenon carboplatin is not free of toxicity, and its use is best restricted to specific indications.
From the Department of Ophthalmology (Drs Mulvihill, Budning, Heon, and Gallie and Ms Vandenhoven) and Division of Hematology-Oncology, Department of Pediatrics (Dr Chan), The Hospital for Sick Children and University of Toronto; and Department of Pathology, Sunnybrook and Women's College Hospital and University of Toronto (Dr Jay); Toronto, Ontario. The authors have no relevant financial interest in this article. Drs Mulvihill and Budning are co–first authors of the article.
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Evaluation of the In vitro and In vivo Antitumor Activity of Histone Deacetylase Inhibitors for the Therapy of Retinoblastoma
Dalgard et al.
Clin. Cancer Res. 2008;14:3113-3123.
ABSTRACT
| FULL TEXT
Subconjunctival Topotecan in Fibrin Sealant in the Treatment of Transgenic Murine Retinoblastoma
Tsui et al.
IOVS 2008;49:490-496.
ABSTRACT
| FULL TEXT
Anecortave Acetate as Single and Adjuvant Therapy in the Treatment of Retinal Tumors of LHBETATAG Mice.
Jockovich et al.
IOVS 2006;47:1264-1268.
ABSTRACT
| FULL TEXT
Periocular Chemotherapy for Retinoblastoma: Success With Problems?
Abramson
Arch Ophthalmol 2005;123:128-129.
FULL TEXT
|
